FY2030 Earnings Estimate for Imunon Issued By HC Wainwright

Imunon, Inc. (NASDAQ:IMNN) – Analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Imunon in a research report issued on Thursday, February 5th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($1.45) per share for the year. The consensus estimate for Imunon’s current full-year earnings is ($1.68) per share.

Other equities analysts have also recently issued research reports about the company. Brookline Capital Management restated a “buy” rating on shares of Imunon in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Imunon currently has a consensus rating of “Hold” and an average price target of $232.50.

Imunon Stock Performance

Shares of NASDAQ:IMNN opened at $3.07 on Friday. Imunon has a one year low of $2.99 and a one year high of $41.22. The stock has a market capitalization of $9.42 million, a price-to-earnings ratio of -0.32 and a beta of 2.14. The company has a 50-day simple moving average of $3.69 and a 200-day simple moving average of $4.93.

Imunon (NASDAQ:IMNN) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.73) by $0.57.

Institutional Investors Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. Riverview Capital Advisers LLC lifted its stake in shares of Imunon, Inc. (NASDAQ:IMNN) by 193.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 34,364 shares of the company’s stock after purchasing an additional 22,649 shares during the quarter. Riverview Capital Advisers LLC owned about 1.41% of Imunon worth $176,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 4.47% of the company’s stock.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.